Eli Lilly’s big-selling insulin, Humalog, faces cut-price competition after the US regulator approved a biosimilar from Sanofi. Sanofi’s Admelog (insulin lispro) is approved in type 1 and type ...
Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...
The pharmaceutical company Novo Nordisk has products sold under the Novolin brand name, and Eli Lilly ... (short-acting), NPH (intermediate-acting), or premixed NPH/regular insulin without a ...
Two years ago, Eli ... insulin market. Lilly has been under pressure in the US over its pricing for insulin products, and earlier this year launched a generic of its own Humalog brand of fast ...
The Egyptian Drug Authority approved the insulin glargine injection manufactured by EVA Pharma through a collaboration with Eli Lilly (LLY). Launched in 2022, the collaboration aims to deliver a ...
Eli Lilly Long-acting GLP-1 analog – incretin mimetic and hypothalamic anorectic agent Launched in 2005 as a treatment for Type 2 diabetes. Currently in Phase II/III trials for the treatment of ...
Columbus joined a slough of cities, states and counties in suing drug companies and pharmacy benefit managers who they say artificially raised insulin ... Wednesday. Eli Lilly, Novo Nordisk ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback